Clinical Trial Update: A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating safety, tolerability, and preliminary clinical activity of Forimtamig-based treatment combinations in relapsed or refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Forimtamig

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED